2/24
08:30 am
cai
Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug
Medium
Report
Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug
2/23
08:46 am
cai
Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
High
Report
Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/23
08:30 am
cai
Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference
Medium
Report
Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference
2/21
02:04 am
cai
Caris Life Sciences (NASDAQ:CAI) was downgraded by analysts at
Wall Stree
Medium
Report
Caris Life Sciences (NASDAQ:CAI) was downgraded by analysts at
Wall Stree
2/17
07:17 am
cai
Caris Life Sciences (NASDAQ:CAI) was given a new $26.00 price target on by analysts at Robert W. Baird.
Low
Report
Caris Life Sciences (NASDAQ:CAI) was given a new $26.00 price target on by analysts at Robert W. Baird.
2/9
08:30 am
cai
Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26
Low
Report
Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26
1/28
08:30 am
cai
Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan
Low
Report
Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan
1/17
01:11 am
cai
Caris Life Sciences (NASDAQ:CAI) was upgraded by analysts at
Wall Street
Low
Report
Caris Life Sciences (NASDAQ:CAI) was upgraded by analysts at
Wall Street
1/13
07:18 am
cai
Capstreet-backed Informativ Names Dominic Brignola as Chief Financial Officer [Yahoo! Finance]
Low
Report
Capstreet-backed Informativ Names Dominic Brignola as Chief Financial Officer [Yahoo! Finance]
1/12
08:32 am
cai
Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect [Yahoo! Finance]
High
Report
Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect [Yahoo! Finance]
1/12
08:30 am
cai
Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results
High
Report
Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results
1/12
08:00 am
cai
Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect
High
Report
Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect
1/5
11:06 am
cai
Caris Life Sciences (NASDAQ:CAI) was given a new $38.00 price target on by analysts at Evercore ISI.
Low
Report
Caris Life Sciences (NASDAQ:CAI) was given a new $38.00 price target on by analysts at Evercore ISI.
1/5
08:41 am
cai
Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
08:30 am
cai
Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/24
08:00 am
cai
Caris Life Sciences: Stronger Fundamentals, Same Conclusion [Seeking Alpha]
Low
Report
Caris Life Sciences: Stronger Fundamentals, Same Conclusion [Seeking Alpha]
12/22
08:02 am
cai
Caris Life Sciences (NASDAQ:CAI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $28.00 to $30.00. They now have a "hold" rating on the stock.
Low
Report
Caris Life Sciences (NASDAQ:CAI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $28.00 to $30.00. They now have a "hold" rating on the stock.
12/19
08:30 am
cai
The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute
Low
Report
The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute
12/17
04:32 pm
cai
Caris Life Sciences (NASDAQ:CAI) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Caris Life Sciences (NASDAQ:CAI) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
12/16
08:56 am
cai
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need [Yahoo! Finance]
Medium
Report
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need [Yahoo! Finance]
12/16
08:30 am
cai
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need
Low
Report
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need
12/11
04:16 pm
cai
Caris Life Sciences (NASDAQ:CAI) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Caris Life Sciences (NASDAQ:CAI) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
12/10
06:24 pm
cai
ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification [Yahoo! Finance]
Low
Report
ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification [Yahoo! Finance]
12/6
04:18 am
cai
Caris Life Sciences (NASDAQ:CAI) is now covered by analysts at
Weiss Ratings. They set a "sell (d)" rating on the stock.
Low
Report
Caris Life Sciences (NASDAQ:CAI) is now covered by analysts at
Weiss Ratings. They set a "sell (d)" rating on the stock.
12/6
03:15 am
cai
Caris Life Sciences (NASDAQ:CAI) was upgraded by analysts at Canaccord Genuity Group Inc. to a "hold" rating.
Low
Report
Caris Life Sciences (NASDAQ:CAI) was upgraded by analysts at Canaccord Genuity Group Inc. to a "hold" rating.